Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates. The
increasing interest in less planar bioactive compounds has given rise to the development of …

A quaternary carbon bears four other carbon substituents or combination of four non-
hydrogen substituents at four vertices of a tetrahedron. The spirocyclic quaternary carbon …

Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in 2004 as an
epigenetic enzyme able to demethylate specific lysine residues of histone H3, namely …

Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid
leukemia (AML) with MLL translocations. The assumption has been that differentiation is …

As a flavin adenine dinucleotide (FAD)-dependent monoamine oxidase, lysine specific
demethylase 1 (LSD1/KDM1A) functions as a transcription coactivator or corepressor to …

Targeted therapy for acute myeloid leukemia (AML) is an effective strategy, but currently
there are very limited therapeutic targets for AML treatment. Histone lysine specific …

Enzymes are common targets in high-throughput screening and related campaigns. An
analysis of papers published between 1990 and 2018 showed that kinases were the most …

LSD1 was the first histone demethylase identified by Professor Shi Yang and his team
members in 2004. LSD1 employs FAD as its cofactor, which catalyzes the demethylation of …

Histone lysine specific demethylase 1 (LSD1) has been recognized as an important
modulator in post-translational process in epigenetics. Dysregulation of LSD1 has been …

Abstract Lysine-specific demethylase 1 (LSD1) is a FAD-dependent enzyme, which has
been proposed as a promising target for therapeutic cancer. Herein, a series of benzofuran …